Agios to take over Alnylam’s preclinical siRNA blood disorder asset in a deal worth $147.5M

Paul Schloesser

Associate Editor

Agios and Alnylam have agreed on an exclusive global licensing deal worth $147.5 million for Agios to take over the development and commercialization of a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Agios to take over Alnylam’s preclinical siRNA blood disorder asset in a deal worth $147.5M

Paul Schloesser

Associate Editor

Sign up to read this article for free.

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

FDA approves Humacyte’s lab-grown blood vessels in milestone for regenerative medicine

Accelerated approval brings Pfizer's BRAF inhibitor to first-line patients

Sofinnova outlines $550M fund after IPOs and M&A deals

Califf, on his way out at FDA, predicts agency tug-of-war between Ramaswamy and RFK Jr.

Agios to take over Al­ny­lam’s pre­clin­i­cal siR­NA blood dis­or­der as­set in a deal worth $147.5M

Paul Schloesser

Associate Editor

Sign up to read this article for free.

more like this

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Agios to take over Alnylam’s preclinical siRNA blood disorder asset in a deal worth $147.5M

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

FDA approves Humacyte’s lab-grown blood vessels in milestone for regenerative medicine

Accelerated approval brings Pfizer's BRAF inhibitor to first-line patients

Sofinnova outlines $550M fund after IPOs and M&A deals

Califf, on his way out at FDA, predicts agency tug-of-war between Ramaswamy and RFK Jr.